(1R,3R,4R,7S)-1-(5-Amino-5-deoxy-beta-D-ribofuranosyloxy)methyl-7-hydroxy-3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane

ID: ALA5205426

Chembl Id: CHEMBL5205426

PubChem CID: 168294533

Max Phase: Preclinical

Molecular Formula: C15H21N3O9

Molecular Weight: 387.35

Names and Identifiers

Canonical SMILES:  NC[C@H]1O[C@@H](OC[C@@]23CO[C@@H]([C@H](n4ccc(=O)[nH]c4=O)O2)[C@@H]3O)[C@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C15H21N3O9/c16-3-6-8(20)9(21)13(26-6)25-5-15-4-24-10(11(15)22)12(27-15)18-2-1-7(19)17-14(18)23/h1-2,6,8-13,20-22H,3-5,16H2,(H,17,19,23)/t6-,8-,9-,10-,11+,12-,13-,15-/m1/s1

Standard InChI Key:  HRFCSXRMLSSQDG-YWKFVXPGSA-N

Alternative Forms

1. Parent:

   

   ALA5205426

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 387.35

Molecular Weight (Monoisotopic): 387.1278

AlogP: -4.01

#Rotatable Bonds: 5

Polar Surface Area: 178.49

Molecular Species: BASE

HBA: 11

HBD: 5

#RO5 Violations: 1

HBA (Lipinski): 12

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 9.70

CX Basic pKa: 8.75

CX LogP: -3.56

CX LogD: -4.67

Aromatic Rings: 1

Heavy Atoms: 27

QED Weighted: 0.33

Np Likeness Score: 1.60

References

1. Kusaka S, Yamamoto K, Shinohara M, Minato Y, Ichikawa S..  (2022)  Design, synthesis and conformation-activity relationship analysis of LNA/BNA-type 5'-O-aminoribosyluridine as MraY inhibitors.,  65  [PMID:35500521] [10.1016/j.bmc.2022.116744]

Source

Source(1):

• Scientific Literature